<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39436840</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1972-2680</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of infection in developing countries</Title><ISOAbbreviation>J Infect Dev Ctries</ISOAbbreviation></Journal><ArticleTitle>Efficacy of favipiravir in COVID-19: A retrospective two center comparative study.</ArticleTitle><Pagination><StartPage>1313</StartPage><EndPage>1319</EndPage><MedlinePgn>1313-1319</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3855/jidc.18039</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Favipiravir (FVP) is an antiviral, targeting RNA-dependent RNA polymerase. We aimed to evaluate the efficacy of FVP as a treatment for COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective study in two centers (San Martino University Hospital in Genova, Italy, and Marmara University Pendik Training and Research Hospital, Turkey). Adult patients (inpatients) diagnosed with COVID-19 between March and June 2020 were included. All patients in the Italian center received the standard of care (SoC) treatment, while in the Turkish center patients received FVP in addition to SoC.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Six hundred-nineteen patients were analyzed (225 from Turkey, all treated with FVP, and 394 from Italy, none treated with FVP). Propensity score-matching was done in 142 patients (71 from the SoC group vs. 71 from the SoC + FVP group). A Higher requirement of NIV/CPAP (n = 38; 53.5%) was registered in the SoC group compared to the SoC + FVP group (n = 9; 12.7%). A higher frequency of intubation was registered in the SoC + FVP group (n = 25; 35.2% vs n = 13, 18.3%). There was a trend towards better survival in SoC + FVP treated patients with HR = 0.64 (95% CI 0.30-1.34). At 28 days the OS was, respectively, 70.3% (95% CI: 53.2-82.1) vs 80.3% (95% CI: 69.0-87.8).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The addition of FVP to SoC did not show a significant difference in survival and invasive and noninvasive (CPAP/NIMV) mechanical ventilation compared to standard of care in moderate and severe COVID-19-infected patients.</AbstractText><CopyrightInformation>Copyright (c) 2024 Elif Tukenmez Tigen, Malgorzata Mikulska, Buket Erturk Sengel, Alessio Signori, Silvia Dettori, Stefania Tutino, Abdullah Emre Guner, Zekaver Odabasi, Volkan Korten, Matteo Bassetti.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tukenmez Tigen</LastName><ForeName>Elif</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Marmara University Pendik Training and Research Hospital, Infectious Disease and Clinical Microbiology, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikulska</LastName><ForeName>Malgorzata</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Ospedale Policlinico San Martino-IRCCS, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erturk Sengel</LastName><ForeName>Buket</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Marmara University Pendik Training and Research Hospital, Infectious Disease and Clinical Microbiology, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Signori</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Genova, Department of Health Sciences- Section of Biostatistics, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dettori</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Ospedale Policlinico San Martino-IRCCS, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tutino</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Ospedale Policlinico San Martino-IRCCS, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guner</LastName><ForeName>Abdullah Emre</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>University of Health Sciences, Public Health, Ä°stanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odabasi</LastName><ForeName>Zekaver</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Marmara University Pendik Training and Research Hospital, Infectious Disease and Clinical Microbiology, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korten</LastName><ForeName>Volkan</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Marmara University Pendik Training and Research Hospital, Infectious Disease and Clinical Microbiology, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassetti</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Ospedale Policlinico San Martino-IRCCS, Genova, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>J Infect Dev Ctries</MedlineTA><NlmUniqueID>101305410</NlmUniqueID><ISSNLinking>1972-2680</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EW5GL2X7E0</RegistryNumber><NameOfSubstance UI="C462182">favipiravir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000577">Amides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011719" MajorTopicYN="Y">Pyrazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000577" MajorTopicYN="Y">Amides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Favipiravir</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword></KeywordList><CoiStatement>No Conflict of Interest is declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39436840</ArticleId><ArticleId IdType="doi">10.3855/jidc.18039</ArticleId></ArticleIdList></PubmedData></PubmedArticle>